1,721,140 research outputs found
Mechanisms of cardiac ischemic pain and coronary angiographic findings in patients with silent ischemia
No full text
Percutaneous Repair for Secondary Mitral Regurgitation
No full textTo the Editor: Obadia et al. (Dec. 13 issue)(1) describe the results of the MITRA-FR trial (Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation), a randomized, controlled trial of this device for percutaneous mitral-valve repair in patients with chronic heart failure and severe secondary mitral-valve regurgitation. The trial showed no clinical benefit for percutaneous correction of functional mitral regurgitation over medical therapy alone. The cardiovascular death rate at 1 year (21.7% in the intervention group and 20.4% in the control group) was unusually high and much higher than the rates reported in the largest real-world MitraClip registries . .
RISCHI E BENEFICI CLINICI DEL TRATTAMENTO CON ANTIAGGREGANTI PIASTRINICI NEL TRATTAMENTO DEL PAZIENTE "FRAGILE" CON SINDROME CORONARICA ACUTA
No full textThe potential benefits of trimetazidine in patients with diabetes and ischemic cardiomyopathy - Reply
No full textHybrid coronary revascularization: promising, but yet to take off
Full text linkHybrid coronary revascularization (HCR) combines arterial coronary artery bypass surgery (most commonly minimally invasive) and percutaneous coronary intervention in the treatment of a particular subset of multivessel coronary artery disease. It was first introduced in the mid-1990s, and aspired to bring together the "best of both worlds": the excellent patency rates and survival benefits associated with the durable left internal mammary artery graft to the left anterior descending artery alongside the good patency rates of drug-eluting stents, which outlive saphenous vein grafts to non-left anterior descending vessels. Although in theory this is a very attractive revascularization strategy, several years later, only one small randomized controlled trial comparing HCR with coronary artery bypass grafting has recently emerged in the medical literature, raising concerns regarding HCR's role and generalizability. In the current review, we discuss HCR's rationale, the current evidence behind it, its limitations and procedural challenges
Plasma beta-thromboglobulin in uncomplicated insulin-dependent diabetes at rest and during physical exercise
No full text- …
